The federal government has dropped its appeal of a preliminary injunction blocking implementation of the Department of Health ...

Discover the major policies of the 1960s' Great Society, their impact on civil rights, education, healthcare, and how they ...

The Trump administration's attempt to overhaul how safety net hospitals pay for outpatient drugs has run into a major legal ...

"Such a change would inflict hundreds of millions of dollars’ worth of annual costs on hospitals and other covered entities." The post 'Does not contain any evidence': Appeals court blocks Trump admin ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

A federal court has blocked the implementation of the 340B rebate pilot, sparing safety-net hospitals from potential cash-flow crises and preserving upfront drug discounts for now. Revenue cycle ...

Add Yahoo as a preferred source to see more of our stories on Google. A lawyer faces sanctions for citing fake cases created by a generative AI tool. (Getty Images) This story was originally published ...

Katherine Denney, Gregory Fliszar Ph.D. A federal judge temporarily blocked the Health Resources and Services Administration (HRSA) from implementing its 340B Rebate Pilot Program (Rebate Program or ...

On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...

PORTLAND, Maine (WMTW) - The U.S. Department of Health and Human Services is appealing after a federal judge in Maine this week ruled that the federal government cannot start making changes to a drug ...

A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements ...

A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.